Morgan Stanley on United Therapeutics Corp. (UTHR): project Tyvaso '2030/2035 risk-adjusted sales in IPF of $1.2bn/$2.5bn'
Go back to Morgan Stanley on United Therapeutics Corp. (UTHR): project Tyvaso '2030/2035 risk-adjusted sales in IPF of $1.2bn/$2.5bn'| United Therapeutics Corp (NASDAQ: UTHR) | Delayed: 538.30 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $538.30 | 52 Week High | $164.04 | |||
| Open | $538.30 | 52 Week Low | $97.52 | |||
| Day High | $538.30 | P/E | 98.41 | |||
| Day Low | $538.30 | EPS | $5.47 | |||
| Volume | 29 | |||||
